TY - JOUR
T1 - Cardiovascular Events After Hematopoietic Stem Cell Transplant
T2 - Incidence and Risk Factors
AU - Vasbinder, Alexi
AU - Hoeger, Christopher W.
AU - Catalan, Tonimarie
AU - Anderson, Elizabeth
AU - Chu, Catherine
AU - Kotzin, Megan
AU - Xie, Jeffrey
AU - Kaakati, Rayan
AU - Berlin, Hanna P.
AU - Shadid, Husam
AU - Perry, Daniel
AU - Pan, Michael
AU - Takiar, Radhika
AU - Padalia, Kishan
AU - Mills, Jamie
AU - Meloche, Chelsea
AU - Bardwell, Alina
AU - Rochlen, Matthew
AU - Blakely, Pennelope
AU - Leja, Monika
AU - Banerjee, Mousumi
AU - Riwes, Mary
AU - Magenau, John
AU - Anand, Sarah
AU - Ghosh, Monalisa
AU - Pawarode, Attaphol
AU - Yanik, Gregory
AU - Nathan, Sunita
AU - Maciejewski, John
AU - Okwuosa, Tochukwu
AU - Hayek, Salim S.
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/12
Y1 - 2023/12
N2 - Background: Hematopoietic stem cell transplantation (HSCT) is associated with various cardiovascular (CV) complications. Objectives: We sought to characterize the incidence and risk factors for short-term and long-term CV events in a contemporary cohort of adult HSCT recipients. Methods: We conducted a multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019. Data on demographics, clinical characteristics, conditioning regimen, and CV outcomes were collected through chart review. CV outcomes were a composite of CV death, myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, and sustained ventricular tachycardia and were classified as short-term (≤100 days post-HSCT) or long-term (>100 days post-HSCT). Results: In 3,354 patients (mean age 55 years; 40.9% female; 30.1% Black) followed for a median time of 2.3 years (Q1-Q3: 1.0-5.4 years), the 100-day and 5-year cumulative incidences of CV events were 4.1% and 13.9%, respectively. Atrial fibrillation/flutter was the most common short- and long-term CV event, with a 100-day incidence of 2.6% and a 5-year incidence of 6.8% followed by heart failure (1.1% at 100 days and 5.4% at 5 years). Allogeneic recipients had a higher incidence of long-term CV events compared to autologous recipients (5-year incidence 16.4% vs 12.1%; P = 0.002). Baseline CV comorbidities were associated with a higher risk of long-term CV events. Conclusions: The incidence of short-term CV events in HSCT recipients is relatively low. Long-term events were more common among allogeneic recipients and those with pre-existing CV comorbidities.
AB - Background: Hematopoietic stem cell transplantation (HSCT) is associated with various cardiovascular (CV) complications. Objectives: We sought to characterize the incidence and risk factors for short-term and long-term CV events in a contemporary cohort of adult HSCT recipients. Methods: We conducted a multicenter observational study of adult patients who underwent autologous or allogeneic HSCT between 2008 and 2019. Data on demographics, clinical characteristics, conditioning regimen, and CV outcomes were collected through chart review. CV outcomes were a composite of CV death, myocardial infarction, heart failure, atrial fibrillation/flutter, stroke, and sustained ventricular tachycardia and were classified as short-term (≤100 days post-HSCT) or long-term (>100 days post-HSCT). Results: In 3,354 patients (mean age 55 years; 40.9% female; 30.1% Black) followed for a median time of 2.3 years (Q1-Q3: 1.0-5.4 years), the 100-day and 5-year cumulative incidences of CV events were 4.1% and 13.9%, respectively. Atrial fibrillation/flutter was the most common short- and long-term CV event, with a 100-day incidence of 2.6% and a 5-year incidence of 6.8% followed by heart failure (1.1% at 100 days and 5.4% at 5 years). Allogeneic recipients had a higher incidence of long-term CV events compared to autologous recipients (5-year incidence 16.4% vs 12.1%; P = 0.002). Baseline CV comorbidities were associated with a higher risk of long-term CV events. Conclusions: The incidence of short-term CV events in HSCT recipients is relatively low. Long-term events were more common among allogeneic recipients and those with pre-existing CV comorbidities.
KW - atrial fibrillation
KW - bone marrow transplant
KW - cardiovascular disease
KW - heart failure
KW - hematopoietic stem cell transplant
KW - risk factor
UR - http://www.scopus.com/inward/record.url?scp=85173146988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173146988&partnerID=8YFLogxK
U2 - 10.1016/j.jaccao.2023.07.007
DO - 10.1016/j.jaccao.2023.07.007
M3 - Article
C2 - 38205002
AN - SCOPUS:85173146988
SN - 2666-0873
VL - 5
SP - 821
EP - 832
JO - JACC: CardioOncology
JF - JACC: CardioOncology
IS - 6
ER -